US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

28.54

+0.11220.39%

Volume:421

Turnover:12.01K

Market Cap:2.57M

PE:- -

High:28.54

Open:28.54

Low:28.54

Close:28.43

52wk High:28.93

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.37

T/O Rate:0.47%

Dividend:0.92

Dividend Rate:3.22%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Why Is Viking Therapeutics Stock (VKTX) Up 32% Today?

Press Release: Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Enlivex Drops RAIN-Token Financing Deal, Halts Planned Private Placement

Roche says Phase II obesity study met both primary endpoints

Why Is Moderna Stock (MRNA) Soaring Today, September 21?

William Blair biotech analyst holds an analyst/industry conference call

Oncopeptides to Present New Pepaxti Data at Key Myeloma Meeting

Wedbush biotech analyst holds an analyst/industry conference call

Avalyn Pharma announces published results from Phase 1 trials of AP02

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

Ultragenyx price target raised to $35 from $32 at Barclays

Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Asep Medical Settles $288,500 in Debt Through Share Issuance

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

Ultragenyx confirms FDA approval of Fayuvi

Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial

Hemab Therapeutics doses first patient in HMB-003 trial

Nuvation Bio announces FDA approval of sNDA for Ibtrozi

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/NVIB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":28.54,"timestamp":1790883486683,"preClose":28.4278,"halted":0,"volume":421,"delay":0,"changeRate":0.003946840768543392,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Trading","change":0.1122,"latestTime":"10-01 15:47:21 EDT","open":28.54,"high":28.54,"low":28.54,"amount":12014.290026,"amplitude":0,"askPrice":28.82,"askSize":100,"bidPrice":28.75,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":28.4278,"nav":28.36,"aum":2552427.21,"dividendRate":0.032172,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.61,"preClose":28.4278,"latestTime":"16:10 EDT","volume":6,"amount":170.5668,"timestamp":1790799005215,"change":0.1822,"changeRate":0.006409,"amplitude":0},"volumeRatio":0.368168},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.368168,"shares":90001,"dividePrice":0.9182,"high":28.54,"amplitude":0,"preClose":28.4278,"low":28.54,"week52Low":24.54,"pbRate":"--","week52High":28.93,"institutionHeld":0,"latestPrice":28.54,"eps":0,"divideRate":0.032172,"volume":421,"delay":0,"ttmEps":0,"open":28.54,"prevYearClose":25,"prevWeekClose":28.0966,"prevMonthClose":28.4278,"prevQuarterClose":28.4278,"fiveDayClose":27.9349,"twentyDayClose":27.8834},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"NVIB","amount":0.23782,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-01","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-01"},{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"},{"executeDate":"2026-09-30","recordDate":"2026-09-30","paymentDate":"2026-10-01","value":0.23782,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669610140","title":"Why Is Viking Therapeutics Stock (VKTX) Up 32% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669610140","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669610140?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:58","pubTimestamp":1790085506,"startTime":"0","endTime":"0","summary":"Viking Therapeutics stock rallied more than 32% on Tuesday following a clinical trial update for weight loss drug VK2735.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-viking-therapeutics-stock-vktx-up-32-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-viking-therapeutics-stock-vktx-up-32-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","THNR","BK4599","NVIB","VKTX","BK4585","HYLG","OZEM","MEDX","BK4139","BK4588","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669739142","title":"Press Release: Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2669739142","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669739142?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (\"Optimi\" or the \"Company\"), a commercial-stage pharmaceutical manufacturer of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","GDOC","BK4007","HYLG","NVIB","OPTH","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669314478","title":"Enlivex Drops RAIN-Token Financing Deal, Halts Planned Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669314478","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669314478?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:27","pubTimestamp":1790080047,"startTime":"0","endTime":"0","summary":"An announcement from Enlivex ( ($ENLV) ) is now available. Enlivex Ltd., a Nasdaq-listed longevity-focused biotech, is developing Allocetra™, an ad...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/enlivex-drops-rain-token-financing-deal-halts-planned-private-placement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/enlivex-drops-rain-token-financing-deal-halts-planned-private-placement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LCLG","NVIB","NQmain","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669414868","title":"Roche says Phase II obesity study met both primary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2669414868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669414868?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:20","pubTimestamp":1790068829,"startTime":"0","endTime":"0","summary":"Roch announced topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide, an investigational, once-weekly dual GLP-1/GIP re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-says-phase-ii-obesity-study-met-both-primary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-says-phase-ii-obesity-study-met-both-primary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JDOC","IDNA","NVIB","HYLG","GDOC","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669160402","title":"Why Is Moderna Stock (MRNA) Soaring Today, September 21?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669160402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669160402?lang=en_us&edition=fundamental","pubTime":"2026-09-22 02:54","pubTimestamp":1790016874,"startTime":"0","endTime":"0","summary":"Moderna shares ($MRNA) surged by more than 14% to about $176 on Monday afternoon. This came after the U.S. pharma and biotech firm announced a key ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-moderna-stock-mrna-soaring-today-september-12?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-moderna-stock-mrna-soaring-today-september-12?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WDNA","BK4534","BK4139","GNOM","IDNA","BK4568","BK4501","BK4551","MRNA","BK4548","MRNX","BK4588","BK4532","NVIB","BK4533","XBIX","BK4585","MRNY","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669253162","title":"William Blair biotech analyst holds an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2669253162","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669253162?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:35","pubTimestamp":1790008535,"startTime":"0","endTime":"0","summary":"Biotech Analyst Minter, along with Ross Summer, MD, discuss updates in idiopathic pulmonary fibrosis ahead of IPF summit conference and expected AL...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/william-blair-biotech-analyst-holds-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/william-blair-biotech-analyst-holds-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4581","XBIX","BK4585","NVIB","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669164926","title":"Oncopeptides to Present New Pepaxti Data at Key Myeloma Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2669164926","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669164926?lang=en_us&edition=fundamental","pubTime":"2026-09-21 23:32","pubTimestamp":1790004777,"startTime":"0","endTime":"0","summary":"Oncopeptides AB ( ($SE:ONCO) ) has provided an update. Oncopeptides AB, a Stockholm-listed biotech focused on hard-to-treat cancers, is using its p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oncopeptides-to-present-new-pepaxti-data-at-key-myeloma-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oncopeptides-to-present-new-pepaxti-data-at-key-myeloma-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2238330802.EUR","LU0210637038.USD","LU0516422366.SGD","BK4566","LU0289960550.SGD","LU0737861269.HKD","LU0048573645.USD","XBIX","LU1242518857.USD","LU1861220207.SGD","LU2125910500.SGD","SG9999014484.SGD","LU0532188223.SGD","LU1839390173.USD","LU0251143029.SGD","NVIB","SG9999002679.SGD","LU0345776255.USD","IE0001KFT4U8.USD","BK4585","LU2177674079.SGD","LU1242518931.SGD","LU0572940350.SGD","LU0175139822.USD","SE","LU0516423174.USD","LU0516423091.SGD","BK4220","IE00BD6J9T35.USD","LU1770036033.HKD","SGXZ58947870.SGD","BK4535","FDNI","BK4551","SG9999014492.USD","SG9999013460.SGD","LU0823038988.USD","LU0572939691.SGD","BK4588","LU2065171311.SGD","LU0499858438.USD","LU2360107671.USD","BK4548","LU1048588211.SGD","LU2152927971.USD","LU2065170008.USD","LU0516422440.USD","LU1861217088.USD","LU2543165471.USD","SG9999001135.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669110169","title":"Wedbush biotech analyst holds an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2669110169","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669110169?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:55","pubTimestamp":1789998926,"startTime":"0","endTime":"0","summary":"Biotech Analyst Zhong, along with Philip J. Mease, MD, of the University of Washington School of Medicine, discuss the positioning of emerging IL-1...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wedbush-biotech-analyst-holds-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wedbush-biotech-analyst-holds-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","BK4581","BK4588","BK4585","NVIB","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669661341","title":"Avalyn Pharma announces published results from Phase 1 trials of AP02","url":"https://stock-news.laohu8.com/highlight/detail?id=2669661341","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669661341?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:10","pubTimestamp":1789996248,"startTime":"0","endTime":"0","summary":"Avalyn Pharma (AVLN) announced that Respiratory Research has published detailed results from two Phase 1 clinical trials of AP02 in healthy volunte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-announces-published-results-from-phase-1-trials-of-ap02-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-announces-published-results-from-phase-1-trials-of-ap02-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","AVLN","HYLG","IDNA","MEDX","NVIB","GDOC","BBC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669316610","title":"InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669316610","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669316610?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:00","pubTimestamp":1789995600,"startTime":"0","endTime":"0","summary":"- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 - - The amended warrants, if exercised i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/21/3365503/0/en/inspiremd-announces-amendments-to-certain-series-j-and-series-k-warrants-providing-potential-gross-proceeds-of-up-to-11-million.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","MRNY","NSPR","BK4585","PSCH","BK4588","BBP","IEIH","RSPH","TBXU","BK4198","MEDI","GDOC","NVIB","IBB","PINK","LFSC","MRNX","BMED","GNMX","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669442151","title":"Ultragenyx price target raised to $35 from $32 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2669442151","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669442151?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:10","pubTimestamp":1789981807,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating on the shares following FDA approval of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","IDNA","TBXU","BMED","BK4588","LABU","PSCH","RSPH","GDOC","BK4139","MRNX","RARE","PINK","SYNB","IBB","MEDI","GNMX","LFSC","TECB","XLVX","MRNY","BK4585","IYH","IEIH","NVIB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668318487","title":"Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2668318487","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668318487?lang=en_us&edition=fundamental","pubTime":"2026-09-20 22:15","pubTimestamp":1789913705,"startTime":"0","endTime":"0","summary":"Cue Biopharma (CUE) announced positive topline results from the Phase 2 clinical trial of CUE-221 conducted in China by Genesis Life Sciences, a re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cue-biopharma-announces-phase-2-trial-of-cue-221-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cue-biopharma-announces-phase-2-trial-of-cue-221-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","CUE","GDOC","BK4139","NVIB","BBC","PSIL","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668186624","title":"Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2668186624","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668186624?lang=en_us&edition=fundamental","pubTime":"2026-09-20 18:00","pubTimestamp":1789898400,"startTime":"0","endTime":"0","summary":"Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling studyPrimary endpoint and the key secondary e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/20/3365072/0/en/cue-biopharma-announces-positive-topline-results-from-cue-221-phase-2-study-in-chronic-spontaneous-urticaria.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","MEDX","NVIB","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668043976","title":"Asep Medical Settles $288,500 in Debt Through Share Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2668043976","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668043976?lang=en_us&edition=fundamental","pubTime":"2026-09-19 07:02","pubTimestamp":1789772544,"startTime":"0","endTime":"0","summary":"The latest update is out from ASEP Medical Holdings Inc ( ($TSE:ASEP) ). Asep Medical Holdings Inc., a biotech-focused investment issuer based in V...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/asep-medical-settles-288500-in-debt-through-share-issuance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/asep-medical-settles-288500-in-debt-through-share-issuance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973580","title":"Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973580","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973580?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:05","pubTimestamp":1789761914,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals (AMRX) “announced that the U.S. Food and Drug Administration has approved its lanreotide injection, 120 mg/0.5 mL, in a ster...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RSPH","BK4588","BK4007","LFSC","GNMX","IBB","TECB","PINK","PSCH","XLVX","SYNB","TBXU","BK4585","GDOC","MRNX","FRTY","BMED","NVIB","MRNY","IDNA","IYH","IEIH","MEDI","AMRX","LABU","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668282679","title":"Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111","url":"https://stock-news.laohu8.com/highlight/detail?id=2668282679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668282679?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:35","pubTimestamp":1789731320,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics (ABEO) “congratulated” Ultragenyx Pharmaceutical (RARE) on the U.S. Food and Drug Administration, FDA, approval of FAYUVI, also...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-congratulated-ultragenyx-on-u-s-fda-approval-of-ux111-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-congratulated-ultragenyx-on-u-s-fda-approval-of-ux111-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","MRNY","PINK","IYH","RARE","XLVX","SYNB","NVIB","RSPH","ABEO","LFSC","MEDI","GDOC","BK4588","BBP","BMED","GNMX","IBB","IDNA","IEIH","PSCH","FRTY","LABU","TECB","TBXU","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994030","title":"Ultragenyx confirms FDA approval of Fayuvi","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994030","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994030?lang=en_us&edition=fundamental","pubTime":"2026-09-18 03:55","pubTimestamp":1789674924,"startTime":"0","endTime":"0","summary":"Ultragenyx (RARE) announced that the U.S. FDA granted standard full approval of Fayuvi, also known as UX111, for the treatment of pediatric patient...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-confirms-fda-approval-of-fayuvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-confirms-fda-approval-of-fayuvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","LABU","NVIB","IDNA","BK4139","LFSC","MEDI","MRNY","GNMX","RSPH","IEIH","FRTY","MRNX","GDOC","TBXU","RARE","XLVX","BBP","BK4588","PSCH","PINK","SYNB","IYH","BK4585","BMED","TECB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668999169","title":"Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668999169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668999169?lang=en_us&edition=fundamental","pubTime":"2026-09-18 00:44","pubTimestamp":1789663452,"startTime":"0","endTime":"0","summary":"Longeveron stock took a 56.14% beating on Thursday after the company posted a failed clinical trial.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/longeveron-stock-lgvn-plummets-56-on-a-failed-clinical-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/longeveron-stock-lgvn-plummets-56-on-a-failed-clinical-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","NVIB","MEDX","HYLG","IDNA","BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668196234","title":"Hemab Therapeutics doses first patient in HMB-003 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668196234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668196234?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:05","pubTimestamp":1789646751,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics (COAG) announced that the first healthy volunteer has been dosed in its Phase 1 clinical trial evaluating HMB-003, an investigat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-doses-first-patient-in-hmb-003-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-doses-first-patient-in-hmb-003-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","MEDX","LENZ","BK4007","HYLG","COAG","BK4539","NVIB","BK4139","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668996120","title":"Nuvation Bio announces FDA approval of sNDA for Ibtrozi","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996120","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668996120?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:35","pubTimestamp":1789644932,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) announced that the U.S. FDA has approved a supplemental New Drug Application for Ibtrozi, a ROS1 inhibitor approved for the tre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-fda-approval-of-snda-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-fda-approval-of-snda-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PINK","IEIH","RSPH","IDNA","LABU","MRNX","GNMX","NVIB","BK4007","TECB","MEDI","FRTY","SYNB","XLVX","PSCH","BK4585","NUVB","GDOC","MRNY","BMED","BBP","LFSC","IBB","TBXU","IYH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}